Proteasome inhibition by peptide-semicarbazones

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 8, 2008, Pages 4579-4588

  Leban, Johann ^a   Blisse, Marcus ^a   Krauss, Babett ^a   Rath, Sandra ^a   Baumgartner, Roland ^a   Seifert, Markus H J ^a  

^a 4SC AG   (Germany)

Author keywords

NF B; Proteasome; Semicarbazone

Indexed keywords

[1 [1 [1 FORMYL 2 (1H INDOL 3 YL)ETHYLCARBAMOYL] 2 (1H INDOL 3 YL)ETHYLCARBAMOYL] 2 (1H INDOL 3 YL) ETHYL]CARBAMIC ACID BENZYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; SEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; REPORTER GENE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NF-KAPPA B; PEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SEMICARBAZONES; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42149111857     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.02.042     Document Type: Article

References (14)

1. Lee D.H., and Goldberg A.L. Trends Cell Biol. 8 (1998) 397-403
2. Groll M., Ditzel l., Lowe J., Stock D., Bochter M., and Huber R. Nature 386 (1997) 463
3. Adams J., Palobella V.J., and Elloitt P. J. Invest. New Drugs 18 (2000) 109
4. Allmond J.B., and Cohen G.M. Leukemia 16 (2002) 433
5. Leban, J. J.; Sherman, D. B.; Sigafoos, J. F.; Spaltenstein, A.; Viveros, O. H.; Wan, D. C. EP 1029 869 B1.
6. Spaltenstein A., Leban J.J., Huang J.J., Reinhardt K.R., Viveros O.H., Sigafoos J., and Crouch R. Tetrahedron Lett. 37 (1996) 1343
7. Spaltenstein, A.; Leban, J.; Sherman, D.; Miller, J.; Huang, J.; Viveros, U.; Sigafoos, J. Keystone Symposium on Proteolytic Enzymes and Inhibitors in Biology, Keystone, CO, March 25-31, 1998.
8. Sharma R.P., Gore M.G., and Akhtar M. J. Chem. Soc., Chem. Commun. 20 (1979) 875-877
9. Adkison K.K., Barrett D.G., Deaton D.N., Gampe R.T., Hassel A.M., Long S.T., McFadyen R.B., Miller A.B., Miller L.R., Payne J.A., Shewchuk L.M., Wells-Knecht K.J., Willard D.H., and Wright L.L. Bioorg. Med. Chem. Lett. 16 (2006) 978-983
10. Schulze-Luehrmann J., and Ghoshi S. Immunity 25 (2006) 701-715
11. Seifert M.H.J. ProPose: steered virtual screening by simultaneous protein-ligand docking and ligand-ligand alignment. J. Chem. Inf. Model. 45 (2005) 449
12. Seifert M.H.J., Schmitt F., Herz T., and Kramer B. ProPose: a docking engine based on a fully configurable protein-ligand interaction model. J. Mol. Model. 10 (2004) 342
13. Gerber P.R., and Müller K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J. Comput. Aided Mol. Des. 9 (1995) 251
14. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, Palo Alto, CA, USA